ReShape Lifesciences Faces Nasdaq Delisting Notice

ReShape Lifesciences ( (RSLS) ) just unveiled an announcement.

On May 28, 2025, ReShape Lifesciences Inc. received a notice from Nasdaq regarding the delisting of its securities due to non-compliance with the minimum stockholders’ equity requirement. Despite an extension granted until May 27, 2025, the company failed to meet the terms. ReShape intends to appeal Nasdaq’s decision, but there is no assurance of a favorable outcome.

Spark’s Take on RSLS Stock

According to Spark, TipRanks’ AI Analyst, RSLS is a Underperform.

ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.

To see Spark’s full report on RSLS stock, click here.

More about ReShape Lifesciences

ReShape Lifesciences Inc. operates in the medical device industry, focusing on providing innovative health solutions.

Average Trading Volume: 701,994

Technical Sentiment Signal: Sell

Current Market Cap: $3.35M

Find detailed analytics on RSLS stock on TipRanks’ Stock Analysis page.